Literature DB >> 10757475

New concepts of Guillain-Barré syndrome.

A K Asbury1.   

Abstract

Guillain-Barré syndrome is an acute autoimmune polyradiculoneuropathy with a clinical presentation of flaccid paralysis with areflexia, variable sensory disturbance, and elevated cerebrospinal fluid protein without pleocytosis. Although Guillain-Barré syndrome previously had been viewed as a unitary disorder with variations, it currently is viewed as a group of syndromes with several distinctive subtypes. These include the principal subtype prevalent in the Western world (acute inflammatory demyelinating polyradiculoneuropathy, and others, each with distinctive electrodiagnostic and pathologic features, including acute motor axonal neuropathy), acute motor-sensory axonal neuropathy, Miller Fisher syndrome, and perhaps others. The clinical and pathologic features of these Guillain-Barré syndrome subtypes are reviewed, and the role of antecedent infections, particularly Campylobacter jejuni gastroenteritis, and the role of antiganglioside antibody responses are reviewed with respect to pathogenesis. Treatment of Guillain-Barré syndrome includes both important supportive measures and immunotherapies, specifically high-dose intravenous immunoglobulin and plasma exchange.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757475     DOI: 10.1177/088307380001500308

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  15 in total

1.  Predictive factors for achieving independent walking in children with Guillain-Barre syndrome.

Authors:  Mohammad Barzegar; Vahideh Toopchizadeh; Mohammad H K Maher; Paria Sadeghi; Fatemeh Jahanjoo; Alireza Pishgahi
Journal:  Pediatr Res       Date:  2017-05-17       Impact factor: 3.756

2.  Guillain-Barré syndrome in children: subtypes and outcome.

Authors:  Zeynep Selen Karalok; Birce Dilge Taskin; Zeliha Brohi Yanginlar; Esra Gurkas; Alev Guven; Aydan Degerliyurt; Ece Unlu; Gulsen Kose
Journal:  Childs Nerv Syst       Date:  2018-06-14       Impact factor: 1.475

3.  Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome.

Authors:  G Nakos; E Tziakou; L Maneta-Peyret; C Nassis; M E Lekka
Journal:  Intensive Care Med       Date:  2005-07-26       Impact factor: 17.440

4.  Ganglioside agglutination immunoassay for rapid detection of autoantibodies in immune-mediated neuropathy.

Authors:  A Alaedini; I Wirguin; N Latov
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

5.  Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome.

Authors:  J Schessl; M Koga; K Funakoshi; J Kirschner; W Muellges; A Weishaupt; R Gold; R Korinthenberg
Journal:  Arch Dis Child       Date:  2006-08-18       Impact factor: 3.791

6.  Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study.

Authors:  Joachim Schessl; Birgit Luther; Janbernd Kirschner; Gottfried Mauff; Rudolf Korinthenberg
Journal:  Eur J Pediatr       Date:  2006-05-12       Impact factor: 3.183

7.  Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coli.

Authors:  H Locht; K A Krogfelt
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

8.  Prognostic model for time to achieve independent walking in children with Guillain-Barré syndrome.

Authors:  Peerada Chaweekulrat; Oranee Sanmaneechai
Journal:  Pediatr Res       Date:  2022-02-15       Impact factor: 3.756

9.  Acute bilateral ophthalmoparesis with pupilary areflexical mydriasis in miller-fisher syndrome treated with intravenous immunoglobulin.

Authors:  Theocharis Papanikolaou; Cath Gray; Bernard Boothman; Gerald Naylor; George Mariatos
Journal:  J Ophthalmol       Date:  2010-09-01       Impact factor: 1.909

10.  Electrophysiological Subtypes and Prognostic Factors of Childhood Guillain-Barré Syndrome.

Authors:  Bahadır Konuşkan; Çetin Okuyaz; Bahar Taşdelen; Semra Hiz Kurul; Banu Anlar
Journal:  Noro Psikiyatr Ars       Date:  2018-06-05       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.